MGTA News and Press, Magenta Therapeutics Inc. From 05/09/19

-- Dosed first subjects in Phase 1 study of MGTA-145 first-line mobilization therapy -- -- Presented updated Phase 2 clinical data on MGTA-456 cell therapy in patients with inherited metabolic disorders at American Academy of Neurology annual meeting -- -- Presented preclinical da...

-- Six-month follow-up on patients with cerebral adrenoleukodystrophy (cALD) shows stable neurological function scores and early and persistent resolution of brain inflammation on MRI -- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel med...

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the closing of its previously announced public offering of 4,887,500 shares of its common stock...

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the pricing of its public offering of 4,250,000 shares of its common stock at a price to the pu...

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that it has launched a proposed public offering of 4,250,000 shares of its common stock. ...

-- Developing novel methods to expand gene-modified stem cells to achieve higher cell doses -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced ...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that it has dosed the first subjects in a Phase 1 study of MGTA-145. Magenta intends to develop MGTA-...

Magenta Therapeutics (NASDAQ: MGTA ): Q4 GAAP EPS of -$0.50  misses by $0.01 . More news on: Magenta Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Declared development candidate in first targeted conditioning program -- -- Phase 1 study for first-line stem cell mobilization program to begin 1H19 -- -- Presented updated clinical data for MGTA-456 cell therapy showing signs of early benefit in patients with inherited metabo...

Gainers:  Soleno Therapeutics (NASDAQ: SLNO ) +210% . Achieve Life Sciences (NASDAQ: ACHV ) +33% . Catasys (NASDAQ: CATS ) +26% . Prana Biotechnology (NASDAQ: PRAN ) +24% . Avid Technology (NASDAQ: AVID ) +23% . Magenta Therapeutics (NASDAQ: MGTA ) +22% . Leap Therapeutics (NASD...